Characterization of membrane materials and membrane coatings for bioreactor units of bioartificial kidneys

Ni, Ming; Teo, Jeremy C. M.; Ibrahim, M. S.; Zhang, Kangyi; Tasnim, Farah; Zink, Daniele; Ying, Jackie Y.

doi:10.1016/j.biomaterials.2010.10.061

Cited by 59 publications

(69 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells are also protected from shear as medium flows through the fibres. However non-uniform cell distribution along the fibres is a common problem, and although being beneficial in terms of support and improved cell growth and performance if adapted to the specific cell type [29], membranes can present a physical barrier against the transport of nutrients and metabolites. As mentioned previously, development from standard hollow fibre bioreactors to multi-compartmental devices such as that in Fig 1 has been a natural progression considering the native architecture of the liver and has been utilised for both clinical and pharmacological applications [22].…”

Section: Perspectives From Established Systems Used Within Pharmaceutmentioning

confidence: 99%

“…Hollow fibre cartridges could also be greatly optimised, as commercially available modules have varying degrees of biocompatibility. Tailoring fibre materials to different cell types and sources have been thought to improve cell performance, and for primary hPTCs it is thought that some of the membrane properties needed include a hydrophilic, negatively charged adhesive surface [29]. When a variety of commercially used membranes, such as regenerated cellulose (RC), PSF/PVP and polyethersulfone (PES)/PVP coated with ECM, were tested with primary hPTCs, performance of the cells was not improved, indicating that these materials are not suitable for use in BAK devices.…”

Section: Device Designsmentioning

confidence: 99%

See 1 more Smart Citation

The use of bioreactors as in vitro models in pharmaceutical research

Ginai

Elsby

Hewitt

et al. 2013

Drug Discovery Today

View full text Add to dashboard Cite

Word TeaserThe development of dynamic 3D bioreactor based systems as in vitro models for use in DMPK studies. Author BiographiesMaaria Ginai graduated with a first Class Bachelors degree with honours in Biomedical Science from the University of Kent (UK) in 2010. She is currently studying a BBSRC CASEfunded PhD at the Centre for Biological Engineering at Loughborough University in the area of bioartificial device progression to in vitro models for use in the pharmaceutical industry. This project is supported by AstraZeneca.Christopher J. Hewitt has a first Class Bachelors degree in Biology from Royal Holloway College, University of London (UK) and a PhD in Chemical Engineering from the University of Birmingham (UK). He is Director of the £7.3M EPSRC Doctoral Training Centre in Regenerative Medicine and co-founder of the £2M Centre for Biological Engineering at Loughborough University (UK). He also leads the Cell Technologies research group whose work spans the Engineering/Life science interface seeking to understand the interaction of the organism with the engineering environment within such diverse areas as microbial fermentation, bio-transformation, cell culture and mostly recently regenerative medicine bioprocessing.Karen Coopman has a first Class Bachelors degree in Pharmacology from the University of Bristol (UK) and a PhD from the Department of Pharmacy and Pharmacology at the University of Bath (UK). She was appointed to a lectureship at Loughborough University, where she is the Operations Manager of the EPSRC-funded Doctoral Training Centre in Regenerative Medicine. She co-leads the Cell Technologies research group within University's Centre for Biological Engineering and is currently a member of the EPSRC's Early Career Forum in Manufacturing Research. The overarching themes of Karen's research are the manufacture of cellular therapies and the use of cells in the drug discovery process. AbstractBringing a new drug to market is costly in terms of capital and time investments, and any development issues encountered in late stage clinical trials may often be due to in vitro -in vivo extrapolations (IVIVE) not accurately reflecting clinical outcome. In the discipline of drug metabolism and pharmacokinetics (DMPK), current in vitro cellular methods do not provide the 3D structure and function of organs found in vivo, so new dynamic methods need to be established to aid improvement of IVIVE. This review will highlight the importance of model progression into dynamic systems for use within drug development, focussing on devices developed currently in the areas of the liver and blood-brain barrier, and the potential to develop models for other organ systems such as the kidney.

show abstract

Section: Perspectives From Established Systems Used Within Pharmaceutmentioning

confidence: 99%

Section: Device Designsmentioning

confidence: 99%

The use of bioreactors as in vitro models in pharmaceutical research

Ginai

Elsby

Hewitt

et al. 2013

Drug Discovery Today

View full text Add to dashboard Cite

show abstract

“…The group of Zink [99] reported an extensive list of surface modifications applied to HFM membranes, among others, poly(maleic anhydride-alt-1-octadecene), oxygen plasma treatment and hydrogen peroxide. These techniques mostly aimed at increasing the presence of carboxylic acid groups on the surface of the membranes.…”

Section:  Chemical Surface Modificationsmentioning

confidence: 99%

“…Collagen IV from human sources appears to be one of the best ECM coatings in both PES/PVP and PET membranes to support the adhesion and function of human PTEC, (HK-2, HPTC, ciPTEC) [82,91,92,99,108]. Interestingly, optimal results were obtained when collagen IV was coated after a first layer of L-dopa, which is shown to be involved in the formation of mussel's adhesive proteins [100].…”

Section: Chaptermentioning

confidence: 99%

See 1 more Smart Citation

Development of an upscaled bioartificial kidney

Chevtchik¹

View full text Add to dashboard Cite

Printed by Gildeprint, Enschede, the Netherlands, Cover design by Natalia Chevtchik and Felix Broens Front page: confocal microscopy image of conditionnaly imrtalized proximal tubule renal epithelial cells (ciPTEC) cultured on polymeric hollow fiber membranes (HFM) with DAPI staining of the nuclei and immunostaining for the tight junction protein ZO-1. The kidneys are composed of hundreds of thousands of filtration units called nephrons (see Figure 1). In the nephron, blood initially passes through the glomerulus where small and middle-size solutes and excess fluids are removed out of the blood by convection. This glomerular filtrate is then transferred to the proximal tubules, which are responsible for reabsorbing essential components of the pre-urine but also for additional removal of a great variety of solutes and wastes from the blood stream, among which, the protein-bound toxins. More details about kidney physiology are explained in chapter 2 of this thesis. DEVELOPMENT OF AN UPSCALED BIOARTIFICIAL KIDNEY Kidney diseaseMore than 10% of the worldwide population is estimated to present a more or less severe form of kidney disease [4][5][6] Chapter 1 4 Renal replacement therapiesThe most common treatment for CKD, ESRD and AKI patients is artificial kidney or dialysis, applied for 2.2 million patients worldwide [10]. This treatment only covers a fraction of the physiological renal function -mostly that of the glomerulus in the normal kidney -and its efficiency in waste removal is incomplete [11, 12]. Indeed, only small water-soluble molecules, inferior to 40 kDa, present in free fraction in the blood, can be eliminated [13] whereas most of the big size and protein bound toxins cannot be removed. Their accumulation is strongly linked to the fatal outcome of the hemodialysed population [14][15][16].These toxins are in large part handled by the proximal tubules in the healthy kidneys [13, 17]. Besides, dialysis is removing a part of the toxin population but is not replacing the kidney endocrine and metabolic physiological functions. The need for a more complete renal replacement therapyThere is a strong need for a device, extracorporeal or implantable, which could fully replace the kidney function. Such a device could be a hybrid combination of polymeric membranes and renal proximal tubule epithelial cells (PTEC), called the bioartificial kidney (BAK). The BAK is conceived to be used in combination with a classical hemofilter [18, 19]. In this way, there is a direct similitude with the natural kidney. First, the glomerular function is replaced by the classical hemodialysis for removal of small size water-soluble molecules.Second, the glomerular filtrate, which comes out of the hemodialysis module, can be processed by the PTEC of the BAK. The principle of application of the BAK is presented in Figure 2.The first BAK prototype was presented by Aebisher et al. in 1987 [21]. Since then, several other prototypes have been proposed by the groups of Humes, Zink and Saito [18,[22][23][24][25][26][27][28][29]. The first...

show abstract

Renal Tubular‐ and Vascular Basement Membranes and their Mimicry in Engineering Vascularized Kidney Tubules

Genderen

Jansen

Cheng

et al. 2018

Adv Healthcare Materials

View full text Add to dashboard Cite

The high prevalence of chronic kidney disease leads to an increased need for renal replacement therapies. While there are simply not enough donor organs available for transplantation, there is a need to seek other therapeutic avenues as current dialysis modalities are insufficient. The field of regenerative medicine and whole organ engineering is emerging, and researchers are looking for innovative ways to create (part of) a functional new organ. To biofabricate a kidney or its functional units, it is necessary to understand and learn from physiology to be able to mimic the specific tissue properties. Herein is provided an overview of the knowledge on tubular and vascular basement membranes' biochemical components and biophysical properties, and the major differences between the two basement membranes are highlighted. Furthermore, an overview of current trends in membrane technology for developing renal replacement therapies and to stimulate kidney regeneration is provided.

show abstract

Characterization of membrane materials and membrane coatings for bioreactor units of bioartificial kidneys

Cited by 59 publications

References 31 publications

The use of bioreactors as in vitro models in pharmaceutical research

The use of bioreactors as in vitro models in pharmaceutical research

Development of an upscaled bioartificial kidney

Renal Tubular‐ and Vascular Basement Membranes and their Mimicry in Engineering Vascularized Kidney Tubules

Contact Info

Product

Resources

About